Vistagen Therapeutics (NASDAQ:VTGN) Given a $4.00 Price Target by Maxim Group Analysts
Maxim Group set a $4.00 price objective on Vistagen Therapeutics (NASDAQ:VTGN) in a research note published on Tuesday, October 15th, TipRanks reports. The brokerage currently has a buy rating on the stock.
Several other equities research analysts have also recently issued reports on VTGN. Chardan Capital reaffirmed a neutral rating on shares of Vistagen Therapeutics in a report on Monday, July 29th. ValuEngine raised Vistagen Therapeutics from a hold rating to a buy rating in a report on Thursday, August 1st. Finally, William Blair reissued a buy rating on shares of Vistagen Therapeutics in a research note on Wednesday, October 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating ...